Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies.

Luigino CalzettaBeatrice Ludovica RitondoPatrizia de MarcoMario Cazzola Rogliani Paola

Published in: Expert review of respiratory medicine (2020)

Triple ICS/LABA/LAMA FDC and dual LABA/LAMA or ICS/LABA FDCs are characterized by specific efficacy/safety profiles in agreement with the level of blood eosinophil count at baseline.

Keyphrases

muscular dystrophy
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
chronic obstructive pulmonary disease
peritoneal dialysis
lung function
cystic fibrosis
patient reported
duchenne muscular dystrophy